About Research at UPMC Hillman Cancer Center

UPMC Hillman Cancer Center is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center - a highly prestigious classification for cancer centers in the U.S. We are the preeminent institution in western Pennsylvania for providing cancer care; conducting basic, translational, clinical, and population science research; and educating the next generation of cancer researchers and physicians.

Image of providers talking and looking at computer screen.

We have more than 300 researchers who collaborate with our clinicians to advance the most promising laboratory studies into novel clinical trials in order to provide patients with early access to new and innovative treatments.

The nationally and internationally renowned research at UPMC Hillman Cancer Center includes a range of disciplines, from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end-of-life care.

We are also dedicated to the education and training of the next generation of cancer researchers and physicians, as well as the ongoing recruitment of world-renowned scientists.

As the only NCI-designated Comprehensive Cancer Center in western Pennsylvania, UPMC Hillman Cancer Center is dedicated to excellence for our patients, and we are working to make vast strides in the global effort to reduce the burden of cancer.

Learn More About

Recent News

Laura Stabile in her research lab at UPMC Hillman Cancer Center.

Pitt Researchers Identify New Target That Could Improve Treatment for Lung Cancer Patients with Brain Metastases

The Pitt /UPMC Hillman research led by Laura Stabile showed that MET amplification occurs more frequently in brain metastases than in primary lung tumors.

Pitt Researchers at UPMC Hillman Cancer Center Demonstrate They Can Turn Cancer Cells Off

A team of researchers from the University of Pittsburgh at UPMC Hillman Cancer Center led by Masashiro Shuda, PhD, showed that treating Merkel cell carcinoma cells caused by Merkel cell polyomavirus with small molecule inhibitors that block CBP/p300 shuts off the viral protein production in cancer cells.

Kathryn Schmitz and Jose Zevallos Announced Deputy Directors of UPMC Hillman Cancer Center

Kathryn Schmitz, PhD, MPH, and José P. Zevallos, MD, MPH, have been selected and agreed to serve as deputy directors of UPMC Hillman Cancer Center.

Learn more about the latest news and accomplishments from UPMC Hillman Cancer Center.